Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08Jamie E. Flerlage, M Link, Barry L. Shulkin et al.|Blood|2026Cited by 2
Metabolic-only response assessment for omission of residual node radiation therapy (RNRT) for patients with classical Hodgkin lymphoma (cHL) and impact on event free (EFS) and overall survival (OS): A report from the Pediatric Hodgkin Consortium’s phase 2 study cHOD17 (NCT03755804).Jamie E. Flerlage, Angela M. Feraco, Yiwang Zhou et al.|Journal of Clinical Oncology|2025Cited by 0
32 | METABOLIC‐ONLY RESPONSE ASSESSMENT ALLOWS RADIATION OMISSION FOR MAJORITY WITH CLASSICAL HODGKIN LYMPHOMA AND MAINTAINS EXCELLENT OUTCOMES: A PHC PHASE 2 STUDY cHOD17Jamie E. Flerlage, Matthias J. Ehrhardt, Angela M. Feraco et al.|Hematological Oncology|2025Cited by 0
METABOLIC-ONLY RESPONSE ASSESSMENT ALLOWS FOR OMISSION OF RESIDUAL NODE RADIATION THERAPY (RNRT) FOR THE MAJORITY OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA (cHL) WHILE MAINTAINING EXCELLENT EVENT FREE (EFS) AND OVERALL SURVIVAL (OS): A REPORT FROM THE PEDIATRIC HODGKIN CONSORTIUM’S PHASE 2 STUDY cHOD17 (NCT03755804)Jamie E. Flerlage, Matthew J. Ehrhardt, Angela M. Feraco et al.|Leukemia Research|2025Cited by 0
Pediatric Hodgkin Consortium Trial Updates: Response-based omission of radiotherapy (RT) for the majority of young people with Hodgkin lymphoma (HL) while maintaining excellent outcomes: Five-year results of HOD08 for low-risk (LR) HL and initial results of cHOD17 high-risk (HR) stratumAngela M. Feraco, Matthew J. Ehrhardt, Jamie E. Flerlage et al.|Klinische Pädiatrie|2025Cited by 0